Case presentation
59 year old gentleman with background of Diabetes and hypertension was diagnosed as a case of chronic myeloid leukemia in the month of April 2018.He was initially started on hydroxyurea for cytoreduction that he received for 2 weeks, afterwards switched to second generation tyrosine kinase inhibitor Dasatinib 100mg/d for 4 weeks. It was terminated because of severe diarrhea. He was then started on Nilotinib, that was also poorly tolerated because of worsening of his diabetes and persistent nausea. Bosutinib, was introduced in june 2018 and was continued till date. Not only he tolerated it well but also showed an exceptionally good, above average response MMR within 4 months. He didn’t suffer from common side effects related to bosutinib such as Diarrhea, pleural effusion or Qtc prolongation.